Pfizer Inc. (NYSE:PFE – Get Free Report)’s stock price was up 0.2% on Monday . The stock traded as high as $26.79 and last traded at $26.72. Approximately 6,565,682 shares changed hands during mid-day trading, a decline of 85% from the average daily volume of 42,656,629 shares. The stock had previously closed at $26.66.
Wall Street Analyst Weigh In
A number of brokerages recently commented on PFE. Guggenheim started coverage on shares of Pfizer in a research report on Friday, February 23rd. They issued a “buy” rating and a $36.00 price objective for the company. TD Cowen cut Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. UBS Group dropped their price objective on Pfizer from $34.00 to $27.00 and set a “neutral” rating on the stock in a report on Thursday, December 14th. Argus lowered shares of Pfizer from a “buy” rating to a “hold” rating in a research report on Friday, March 22nd. Finally, Barclays cut their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating for the company in a report on Thursday, December 14th. Twelve investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $36.88.
Pfizer Stock Performance
The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91. The company has a market capitalization of $150.51 billion, a PE ratio of 73.83, a PEG ratio of 1.19 and a beta of 0.61. The company has a 50 day moving average price of $27.36 and a 200 day moving average price of $29.10.
Pfizer (NYSE:PFE – Get Free Report) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.19) by $0.29. Pfizer had a net margin of 3.62% and a return on equity of 10.88%. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period last year, the business earned $1.14 EPS. The firm’s revenue for the quarter was down 41.3% compared to the same quarter last year. Equities analysts forecast that Pfizer Inc. will post 2.22 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of PFE. Rowlandmiller & PARTNERS.ADV boosted its position in Pfizer by 14.0% during the 1st quarter. Rowlandmiller & PARTNERS.ADV now owns 78,868 shares of the biopharmaceutical company’s stock valued at $2,189,000 after purchasing an additional 9,702 shares during the period. Bath Savings Trust Co grew its position in Pfizer by 10.1% in the 1st quarter. Bath Savings Trust Co now owns 45,820 shares of the biopharmaceutical company’s stock worth $1,272,000 after purchasing an additional 4,205 shares during the last quarter. Tompkins Financial Corp increased its position in Pfizer by 6.3% in the 1st quarter. Tompkins Financial Corp now owns 46,234 shares of the biopharmaceutical company’s stock valued at $1,283,000 after acquiring an additional 2,749 shares during the period. Atlas Brown Inc. lifted its holdings in Pfizer by 4.8% in the first quarter. Atlas Brown Inc. now owns 70,182 shares of the biopharmaceutical company’s stock worth $1,948,000 after purchasing an additional 3,236 shares during the period. Finally, GAMMA Investing LLC lifted its position in Pfizer by 9.1% in the first quarter. GAMMA Investing LLC now owns 13,768 shares of the biopharmaceutical company’s stock worth $382,000 after purchasing an additional 1,149 shares during the period. Institutional investors own 68.36% of the company’s stock.
About Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.